We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Childhood Sarcoma Increases Risk of Blood Clots

By Biotechdaily staff writers
Posted on 01 May 2007
Children and young adults with a form of cancer called sarcoma are at increased risk of having a thromboembolic event (TE) in their veins. More...


Thromboembolic events involve a blood clot in a vessel that can interfere with normal blood flow. Clots can sometimes break loose and travel through the blood stream to form new clots at locations in the body where they can be life threatening. TEs are almost always treatable if detected early. Investigating the association between sarcoma and TE is important because the majority of children with sarcoma can be cured of their cancer, but the occurrence of TEs could adversely affect this success.

The research was carried out by scientists at the U.S. National Cancer Institute (NCI; Bethesda, MD, USA), part of the National Institutes of Health, who also found that pediatric patients whose cancer had spread beyond the original cancer site were more likely to develop a TE than those with localized cancer. These findings are from a study reported in the April 20, 2007, issue of the Journal of Clinical Oncology. Researchers reviewed patient records for 122 children and young adults treated for sarcoma in the Pediatric Oncology Branch of the NCI between October 1980 and July 2002.

Cancer creates an environment that is conducive to thrombosis because of the propensity of tumor cells to promote coagulation as well the secretion of cytokines, or signaling compounds, that trigger inflammation. In addition, factors common to cancer patients, such as chemotherapy, surgery, immobilization, having a central venous access device (such as a central line), and having other diseases or conditions, all increase a person's risk for blood clots.

The study results showed that, over the 22-year study period, 16% of children and young adults with sarcoma developed a TE. However, the researchers noted that this figure probably underestimates the true frequency of TEs in this pediatric patient population. Since this was a retrospective study of archival patient records, most of the original physicians may not have specifically looked for TEs, so some blood clots would have gone unrecorded. Also, TEs often are asymptomatic and early screening was less accurate. As the study observed, the rate at which TEs were detected in sarcoma patients increased from 7% before 1993 to 23% since 1993--an increase they attributed to improved screening techniques.

Children whose cancer had spread to other parts of the body were 2.5 times more likely to develop a TE than those whose disease was localized. The most common locations of the blood clots were in the deep veins of the legs and arms, the lungs (pulmonary embolism), and the inferior vena cava, which is the large vein that carries blood from the lower half of the body to the heart. Of the patients who developed a TE, 40% had no symptoms related to their blood clot. Thromboses were often detected around the same time as the cancer diagnosis.

Previous research had shown a link between cancer and TEs in adults, but data regarding TEs in adults may not be applicable to children with cancer. Children differ from adults in the types of cancer that occur, as well as in the number and types of co-morbid conditions. The researchers only looked at sarcomas (cancers of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue) in children, so not all pediatric cancer types were represented. Sarcomas account for 15 to 20% of pediatric cancers and include rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma. Approximately two-thirds of these cases can be cured.

A total of 23 TEs occurred in 19 of the 122 patients during the 22-year period of record keeping. Twenty-three percent of patients with metastatic cancer developed a TE, compared to 10% of patients with localized cancer, suggesting an association between tumor burden and the risk of TE.


Related Links:
National Cancer Institute

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Thyroid Test
Anti-Thyroid EIA Test
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.